Enran Chuangtou
VC Fund
Enran Chuangtou is an investment firm.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Enran Chuangtou invests in
Stages Enran Chuangtou invests in
Countries Enran Chuangtou invests in
Investment Focus
Industry
- Biotechnology 4 (40%)
- Pharmaceutical 3 (30%)
- Health Care 2 (20%)
- Life Science 2 (20%)
- Laser 1 (10%)
Stage
- Series A 3 (30%)
- Series C 3 (30%)
- Angel 1 (10%)
- Series E 1 (10%)
- Venture - Series Unknown 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Shenji Miaokong
|
Hangzhou Shenji Miaokong Technology Co., Ltd. is an early-stage Chinese medical technology startup. The company specializes in the highly advanced field of invasive brain-computer interfaces (BCIs) and clinical neural translation. | Angel / May 22, 2026 | |
Artec Bio
|
Artec Bio is an innovative biotechnology company that specializes in the development of next-generation protein degradation drugs, leveraging cutting-edge research and technology to target and eliminate disease-causing proteins. | Series A / Feb 02, 2026 | |
| BV Laser is a manufacturer of medical beauty equipment. | $14.2M / Series C / Dec 15, 2025 | ||
|
Zhimeixingchen
|
Zhimeixingchen is a forward-thinking technology company specializing in the development and delivery of AI-powered skincare applications and services. | Series A / Sep 11, 2025 | |
| InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equippedwith global-level top-notch know-how and efficient execution capabilities. | $34M / Series C / Aug 22, 2025 | ||
| NanoRibo is an innovative biopharmaceutical developer, focusing on cutting-edge biopharmaceuticals and new vaccine research and development. | Series A / Feb 10, 2025 | ||
| SinoTau is a total solution provider specializing in generic drugs and innovative drugs. | $151.9M / Series E / Jul 03, 2023 | ||
| Leads Biolabs is a pharmaceutical company that develops medicines and treatments for tumors. | $100M / Series C / Oct 08, 2021 | ||
| Leads Biolabs is a pharmaceutical company that develops medicines and treatments for tumors. | Venture - Series Unknown / Oct 28, 2020 | ||
| Leads Biolabs is a pharmaceutical company that develops medicines and treatments for tumors. | Venture - Series Unknown / Apr 18, 2019 |
Co-Investors
Huaige Capital
3 deals together
KPC
2 deals together
CAS Star
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Enran Chuangtou invest in?
Enran Chuangtou invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series C stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Enran Chuangtou last invest?
The most recent investment recorded for Enran Chuangtou closed in May 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
